EVOLVE
Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 3,883 haemodialysis patients with secondary hyperparathyroidism, cinacalcet did not significantly reduce death or cardiovascular events compared with placebo.
N
3883
Disegno
Double-blind RCT
Esito
Composite of death or first non-fatal cardiovascular event
Rilevanza
2
Risultato48.2% vs 49.2%; HR 0.93 (95% CI 0.85–1.02; p=0.11); age-adjusted HR 0.88.
Chertow GM, et al. N Engl J Med. 2012;367(26):2482-2494. 10.1056/NEJMoa1205624
Discussione e critica
No universal CV benefit; high dropout and crossover; cinacalcet is now used selectively in refractory disease.